(Q40904943)

24 September 2017

1 reference

title

Adjuvant medical therapy for colorectal cancer (English)

1 reference

24 September 2017

1 reference

Diaz-Canton EA

1

1 reference

24 September 2017

Pazdur R

series ordinal

2

1 reference

24 September 2017

publication date

1 February 1997

1 reference

Surgical Clinics of North America

24 September 2017

published in

1 reference

24 September 2017

volume

77

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

211-228

1 reference

Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Survival after postoperative combination treatment of rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Prolongation of the disease-free interval in surgically treated rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

An overview of adjuvant therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Allelic loss of chromosome 18q and prognosis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Effective surgical adjuvant therapy for high-risk rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Preoperative infusional chemoradiation therapy for Stage T3 rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Postoperative radiation therapy for high-risk colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970540-5

7 January 2021

10.1016/S0039-6109(05)70540-5

Identifiers

DOI

1 reference

24 September 2017

1 reference